Buying At The Close Drives VirnetX To $7.50 Oct. 4, 20172 Comments VirnetX Up 100%, NBEV Hits $7 Jun. 5, 20171 Comment NBEV Now A 20X Trade May 26, 2017NBEV3 Comments NBEV Rises 40% In 3 Days May 19, 2017NBEV Catasys Jumps 44% Today Mar. 15, 2017CATS GW Pharma Demonstrates Cannabis Efficacy In Treating Cancer Feb. 7, 2017 Due Diligence Or Die Jan. 23, 20175 Comments 2016 Results Jan. 9, 20172 Comments VirnetX Drop Provided Buying Opportunity Dec. 9, 20161 Comment Cannabis Sector Continues To Outperform Dec. 2, 2016 Amedica Jumps Again On 510K Clearance Nov. 21, 2016AMDA4 Comments Blackline Up 64% In 3 Weeks Nov. 18, 2016BL NBEV: Anatomy Of A 10 Bagger Nov. 18, 20163 Comments NBEV Shows How It's Done Nov. 16, 20163 Comments NBEV Jumps 16 Percent Today Nov. 11, 20162 Comments The Ferrari Factor Nov. 10, 2016 Aphria Continues To Impress Oct. 28, 2016 Microcap Heaven: New Long Position Rises 7X Oct. 27, 2016 IPCI Up 10% Today Oct. 19, 2016IPCI1 Comment Good Week For IP Trades Oct. 3, 2016VHC, ACTG Cannabis Stocks Rally Sep. 19, 20165 Comments 70% Profit On Acacia Sep. 15, 2016ACTG Catasys: $.30 To $1.55 Is A Good Trade Sep. 8, 2016CATS2 Comments GW Pharmaceuticals Up 24% Today Sep. 7, 20162 Comments Due Diligence Pays Off, Tonix Drops 60% On Clinical Data Sep. 7, 20164 Comments My Worst Trade Of The Year Is Finally Profitable Sep. 2, 2016 Cynapsus, Jumps Over 100% On Buyout Aug. 31, 2016 Marathon And Catasys Performing Well Jul. 18, 2016 Bucha: This $1 Stock Is Now Worth Over $7 Jul. 8, 2016NBEV20 Comments I More Than Doubled My Position In ChromaDex Jun. 29, 2016 2016 Has Been Profitable May 31, 20163 Comments Titan Pharmaceuticals Up 3X May 27, 2016TTNP Marathon Will Report Monster Profits This Quarter May 16, 2016MARA2 Comments GTXO Surges 4X On Patent News May 11, 2016GTXO Titan Pharmaceuticals Up Over 100% Apr. 13, 2016 Top Trades For Q1 2016 Mar. 21, 2016 VirnetX Share Price Could Double This Week Feb. 3, 2016VHC9 Comments Results For All Trades Jan. 6, 2016 2015 Results Jan. 4, 201614 Comments Receive Trade Alerts Nov. 2, 2015 Telesta Therapeutics: Near-Term Catalyst Could Provide Multi-Bagger Returns Oct. 28, 2015BNHLF116 Comments Chanticleer's Share Price Could Surge Next Week Sep. 18, 20158 Comments MabVax: Near-Term Catalysts Could Push Shares From $2 To Over $5 Jul. 1, 20153 Comments GTX Announced Another State Has Come On Board With Reimbursement Jun. 9, 2015 GTX's Lead Product Just Validated By Medi-Cal Apr. 8, 2015GTXO4 Comments Forget Shake Shack, Chanticleer Could Provide More Than A 2X Return Mar. 13, 20155 Comments GTX: This Wearable Tech Company Could Deliver 6X Short-Term Returns Feb. 24, 201521 Comments 2014 Results Jan. 12, 2015 I Am Long Cynapsus Therapeutics Nov. 6, 201417 Comments One Of The Best Biotech Trades I Have Ever Encountered Nov. 3, 20147 Comments USell: Why This $2 Stock Should Be Trading Above $6 Today Sep. 17, 20147 Comments Google's And Facebook's Drone Investments Make Drone Aviation My Top Pick Sep. 3, 2014DRNE-OLD28 Comments Receive Free Trade Alerts May 2, 20141 Comment Mission Statement Jan. 1, 20141 Comment Could ChromaDex's Niagen Reverse The Aging Process? Possibly Dec. 24, 2013CDXC1 Comment Trading Results 2013 Dec. 11, 20132 Comments BioZone Update Nov. 13, 2013COCP The Power Of Goldman Jul. 16, 2013 2013 Halftime Report Jul. 16, 2013 $6 Million Biotech Should Provide A Short-term Double May 28, 20139 Comments Dr. Phillip Frost Increases Investment In MusclePharm Jan. 28, 2013 2011 And 2012 Trading Results Jan. 2, 20132 Comments Major League Athletes Confirm Muscle Pharm Product Efficacy Dec. 31, 2012MSLP Continuing To Trade Vringo Calls Oct. 9, 20121 Comment VirnetX Remains Strong Despite Bear Raid Aug. 3, 2012VHC1 Comment Current Securities Disclaimer And Disclosure Jul. 24, 2012 It Looks Like Apple Wants To Settle With Virnetx May 30, 2012VHC4 Comments Isoray Featured On Discovery Channel May 22, 2012ISR Markman Ruling Favorable For Virnetx Apr. 26, 2012 Virnetx Has A Lot Going On Behind The Scenes Apr. 25, 20121 Comment Avaya May Be Delaying Its IPO Mar. 30, 2012 Securities Disclaimer And Disclosure Mar. 21, 2012SNOA Security Disclaimer And Disclosure Mar. 7, 2012 Securities Disclaimer And Disclosure Feb. 9, 2012SNOA EXAR, a struggling semiconductor company selling at near cash Jan. 10, 2012EXAR Securities disclaimer and disclosure Nov. 16, 2011 Virnetx article correction Jun. 15, 2011VHC1 Comment Insmed up over 100% in three months Jun. 14, 2011INSM4 Comments What's the real value of VHC? Apr. 9, 20111 Comment VHC buyout options Apr. 8, 2011 VHC's new patent provides leverage in potential buyout negotiations. Apr. 5, 20119 Comments VHC, possible buyout or patent infringement settlements this year Mar. 31, 2011 My investment strategy Jan. 26, 2011 VHC, potentially huge payoff in 2011 Dec. 22, 2010VHC2 Comments Insmed's new deal Dec. 7, 2010INSM3 Comments When things look bad, opportunity exists Nov. 13, 2010 Searching for market inefficiency Oct. 26, 2010 A shareholder tours the oculus manufacturing facility Oct. 6, 2010SNOA Insmed still priced in the ridiculous zone Sep. 14, 2010INSM Insmed has gotten too cheap! Jun. 24, 2010INSM Microtune, a great company selling just above cash. May 12, 2010TUNE
Don't miss any articles by John H. Ford Join Seeking Alpha to get real-time alerts on your favorite authors.
John H. Ford John H. Ford's Blog Deep Value, special situations Send Message Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Amedica Jumps Again On 510K Clearance Nov. 21, 2016 12:13 PM ET|Includes: Amedica Corporation (AMDA) Just over 2 weeks ago, Amedica was trading at $.60. Today it hit $1.09, an 81% gain. I closed out my entire position, and may buy again on dip. Amedica has been a phenomenal trading vehicle.
Today's 510K approval doesn't appear that significant. Cascade 510K approval is still the big catalyst and could come at any time. This is your classic high risk high reward binary trade.
Disclaimer and disclosure: It is probable that the author and his associates have a position in the subject securities consistent with the opinion expressed in this article and they reserve the right to buy and/or sell the securities mentioned in this article, at any time without further notice. For complete disclosure and disclaimer information please click here.
Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in AMDA over the next 72 hours.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
